Jan 30, 2020
Rani Therapeutics Announces Positive Phase I Study Results of Oral Octreotide using RaniPill(TM)
Dec 12, 2019
Global Somatostatin Analogs Industry Outlook, 2019-2026 - Pasireotide Estimated to Be the Fastest Growing Segment Over the Forecast Period
Nov 07, 2019
CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement For Octreotide Long Acting Injectable (LAI) Microsphere For Neuroendocrine Cancers And Acromegaly
Jun 20, 2019
Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly
Feb 13, 2018
Health Canada approves Ipsen's Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)
Jan 30, 2018
FDA Grants Orphan Drug Designation to Dauntless Pharmaceuticals' DP1038 for the Treatment of Acromegaly
Jan 26, 2018
FDA approves new treatment for certain digestive tract cancers
Oct 19, 2017
Clinical Data from Phase 1 PK/PD Study of Octreotide for Intranasal Delivery to be Presented at North American Neuroendocrine Tumor Society Symposium
Sep 19, 2017
European Commission Approves XERMELO® (Telotristat Ethyl) For The Treatment Of Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy
Sep 07, 2017
Lexicon Pharmaceuticals Announces Four Data Presentations At The European Society Of Medical Oncology 2017 Congress
Aug 01, 2017
Lexicon Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides A Business Update
Jul 21, 2017
Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo® (Telotristat Ethyl)